Quantcast

Xel Completes Development of Prototype Transdermal Patch for Alzheimer’s

September 11, 2008

Xel Pharmaceuticals has completed the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer’s disease. The prototype transdermal patch can deliver 400800mcg of Huperzine A per day for up to seven days.

Huperzine A is said to be a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades in China as a prescription medication for the treatment of dementia. It is a potent, highly selective and reversible inhibitor of acetyl cholinesterase.

Danyi Quan, chief scientific officer of Xel, said: “Huperzine A is one of our most promising and successful transdermal products. Its low therapeutic dose and molecular weight makes Huperzine A ideal for transdermal drug delivery. Our once-a-week transdermal patch is a clearly preferable treatment method to AD patients and caregivers. The prototype Huperzine A transdermal patch is ready for investigational new drug filing and further development.”

Wade Xiong, president and CEO of Xel, said: “We are delighted to announce the completion of the development of our prototype Huperzine A transdermal patch. Xel’s business strategy is to identify compounds having proven safety and efficacy, and to further develop advanced drug delivery systems in order to provide better delivery profiles, as well as patent protection. Currently, Xel has several co-development and licensing opportunities available for major pharmaceutical companies.”




comments powered by Disqus